Corvus Pharmaceuticals (CRVS) Cash from Financing Activities (2015 - 2026)

Corvus Pharmaceuticals' Cash from Financing Activities history runs 11 years deep, the most recent figure standing at $190.7 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 68267.74% year-over-year to $190.7 million; the TTM figure through Mar 2026 stood at $226.9 million (up 1098.16% YoY), while the FY2025 annual figure was $36.4 million, down 25.7% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $190.7 million, up from $20000.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $190.7 million in Q1 2026, with the low at $4000.0 in Q1 2023.
• The 4-year median for Cash from Financing Activities is $347500.0 (2023), against an average of $25.4 million.
• The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities tumbled 99.89% in 2025, then jumped 68267.74% in 2026.
• Corvus Pharmaceuticals' Cash from Financing Activities stood at $335000.0 in 2023, then soared by 5454.63% to $18.6 million in 2024, then sank by 99.89% to $20000.0 in 2025, then jumped by 953630.0% to $190.7 million in 2026.
• Business Quant data shows CRVS's Cash from Financing Activities at $190.7 million in Q1 2026, $20000.0 in Q4 2025, and $360000.0 in Q3 2025.